期刊
JOURNAL OF HEPATOLOGY
卷 49, 期 2, 页码 192-197出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2008.04.014
关键词
portal hypertension; NOS uncoupling; NO biodisponibility
资金
- Ministerio de Educacion y Ciencia [SAF 2007-61298]
- Fondo de Investigaciones Sanitarias [FIS 06/0623]
- Instituto de Salud Carlos III
Background/Aims: Tetrahydrobiopterin is an essential cofactor for NOS enzymes to synthesize NO. It has been suggested that reduced intrahepatic tetrahydrobiopterin decreases intrahepatic NO and contributes to increase hepatic vascular resistance and portal pressure in cirrhosis. The main aim of the study was to evaluate the effect of tetrahydrobiopterin supplementation in portal pressure in CCl4 cirrhotic rats. Methods: Cirrhotic rats received vehicle or tetrahydrobiopterin (10 mg/kg/day i.p.) for 3 days. Hepatic and systemic hemodynamics and hepatic tetrahydrobiopterin, NOS activity and cGMP levels were measured. In addition, hepatic and systemic hemodynamics were evaluated in normal rats in which tetrahydrobiopterin deficiency was induced by administrating 2,4-diamino-6-hydroxy-pyrimidine (DAHP) for 8 h. Results: In cirrhotic rats, tetrahydrobiopterin administration increased liver NOS activity and cGMP levels and markedly and significantly reduced portal pressure. Amelioration of portal hypertension was associated with a normalization of arterial pressure. In normal rats DAHP decreased hepatic tetrahydrobiopterin and NOS activity and increased hepatic vascular tone. These effects of DAHP administration were corrected by tetrahydrobiopterin supplementation. Conclusions: The present study shows that tetrahydrobiopterin markedly reduces portal hypertension and improves systemic hemodynamics; in cirrhotic rats. These data support the concept that tetrahydrobiopterin supplementation may represent a new therapeutic strategy for portal hypertension. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据